FECAL MICROBIOTA TRANSPLANTATION: A REVOLUTIONARY THERAPY FOR METABOLIC DISORDERS

Recent interest in the role of gut microbiota in metabolism has led to exploration of fecal microbiota transplantation (FMT) as a therapy for metabolic disorders, including obesity. However, its effectiveness remains unclear. This review analyzed studies published between 2019 and 2025 from PubMed and Google Scholar using the keywords "obesity" and "FMT". Findings indicate that FMT can reduce insulin resistance, as evidenced by decreased HOMA-IR levels. In several trials, improved glucose tolerance and lipid profiles were also observed, suggesting broader metabolic benefits. Donor selection and recipient compatibility emerged as important factors influencing outcomes, highlighting the need for standardized protocols. Most studies reported significant gut microbiota shifts post-FMT, including increased Bacteroides/Firmicutes ratios and higher Bifidobacterium and Lactobacillus abundance. Only one study found no significant metabolic improvements. FMT appears promising for metabolic disorder treatment, particularly alongside diet, lifestyle changes, or bariatric surgery. Given these findings, FMT may serve as a valuable adjunct in obesity management, though not a standalone cure. Further large-scale studies are needed to confirm its therapeutic potential.